These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 19452131)

  • 1. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.
    Perez-Soler R; Zou Y; Li T; Ling YH
    Clin Cancer Res; 2011 Nov; 17(21):6766-77. PubMed ID: 21914790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
    Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
    Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
    Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
    Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
    Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
    Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in EGFR-directed therapy in head and neck cancer.
    Numico G; Silvestris N; Grazioso Russi E
    Front Biosci (Schol Ed); 2011 Jan; 3(2):454-66. PubMed ID: 21196389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
    Rudin CM; Liu W; Desai A; Karrison T; Jiang X; Janisch L; Das S; Ramirez J; Poonkuzhali B; Schuetz E; Fackenthal DL; Chen P; Armstrong DK; Brahmer JR; Fleming GF; Vokes EE; Carducci MA; Ratain MJ
    J Clin Oncol; 2008 Mar; 26(7):1119-27. PubMed ID: 18309947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
    Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
    Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.
    Eriksen JG; Kaalund I; Clemmensen O; Overgaard J; Pfeiffer P
    Support Care Cancer; 2017 Jul; 25(7):2179-2185. PubMed ID: 28197850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
    Steins MB; Reinmuth N; Bischoff H; Kindermann M; Thomas M
    Onkologie; 2010; 33(12):704-9. PubMed ID: 21124044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents.
    Rhee J; Oishi K; Garey J; Kim E
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S101-6. PubMed ID: 16336749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skin problems and EGFR-tyrosine kinase inhibitor.
    Kozuki T
    Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.